A target‐mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans

Abstract

This mechanism-based model accurately predicted VEGF concentrations and allowed for the simulation of various rhVEGF(165) dose regimens that may aid in optimization of drug delivery for future clinical trials.

Terapia gênica com VEGF para angiogênese na angina refratária: ensaio clínico fase I/II

“…Other previous reports used the same therapy, but in association with coronary artery bypass surgery, among others [7][8][9][10][11][12][13][14][15][16][19][20][21]. Two previous studies [17,18] similar to ours in that respect showed controversial results, one showing an improvement of myocardial perfusion and angina [17] and another only improvement in angina [18].…”

“…Three months after intervention we observed improvements in scintigraphic SSS scores (18.38 ± 7.51 vs. 15.31 ± 7.29, P = 0.003) and SRS (11.92 ± 7.49 vs. 8.53 ± 6.68, P = 0.002) but not in proportion to the areal extent of ischemic Rev Bras Cir Cardiovasc 2010; 25(3): 311-321 of administration of VEGF. Clinical trials bring controversial results, many showing evidence of clinical improvement and angiogenesis [8][9][10][11][12][13][14][15][16][17][18][19] and others showing no differences in myocardial perfusion when compared to their controls [7,20]. Thus, although promising, remain still not completely clear the clinical effects on the myocardium vascularization of the therapy with VEGF in its various forms and ways of administration, justifying further studies.…”

“…The vascular endothelial growth factor (vascular endothelial growth factor -VEGF) has been the focus of several studies [5,6] and its effects are being tested in patients with severe CAD [7][8][9][10][11][12][13][14][15][16][17][18][19][20]. Studies use different doses, vectors and ways Conclusions: The therapy has proved to be safe and feasible in this series of patients.…”

Arterio-venous gradients of IL-6, plasma and serum VEGF and D-dimers in human cancer

“…These observations suggest that serum VEGF-A might be derived from other sources. However, it might be possible that continuous spilling of tumour-derived VEGF in the circulation might lead, especially considering the half-life of VEGF-A of about 30 min (Eppler et al, 2002), to equivalent levels of venous and arterial VEGF-A.…”

A Maternally Sequestered, Biopolymer‐Stabilized Vascular Endothelial Growth Factor (VEGF) Chimera for Treatment of Preeclampsia

“…These include administration of exogenous growth factors that bind Flt‐1 and sFlt‐1, including VEGF and placental growth factor,37, 38 thereby sequestering sFlt‐1 and restoring angiogenic balance and bioavailable VEGF. However, a potential limitation of this approach is that exogenously administered growth factors possesses a brief plasma half‐life and are prone to degradation 39. This limitation can be overcome by fusion of growth factors with a biopolymer synthetic protein based on human elastin 40, 41.…”